Cancer Treatment News and Research

RSS

Researchers create new computational model to understand animal cell behavior

Biological systems, including cells, tissues and organs, can function properly only when their parts are working in harmony. These systems are often dauntingly complex: Inside a single cell, thousands of proteins interact with each other to determine how the cell will develop and respond to its environment.

24 Mar 2011

John Muir Health provides new cancer treatment using Varian's RapidArc radiation therapy

John Muir Health is offering a new cancer treatment option using the latest technology from Varian Medical Systems - The Trilogy Linear Accelerator with RapidArc Technology. The new accelerator, located at John Muir Medical Center, Concord, significantly shortens treatment sessions from 15-20 minutes to 2-5 minutes, while improving the precision of the radiotherapy.

24 Mar 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

SCCA, ProCure to open new proton therapy center for cancer treatment

Seattle Cancer Care Alliance, together with ProCure Treatment Centers Inc., today held its ceremonial groundbreaking on a new proton therapy center in north Seattle that will provide a first-of-its-kind treatment option for cancer patients throughout the Northwest.

23 Mar 2011

Five year course of tamoxifen can offer long-term benefit for women with breast cancer

Experts are urging breast cancer patients to complete their full prescription of tamoxifen, following long-term results from a major Cancer Research UK-funded trial which showed the cancer was less likely to come back in women who took the drug for five years, compared to two years.

22 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Cancer Care Partners first in U.S. to use new, advanced cancer treatment

On March 7, 2010, Cancer Care Partners became the first cancer center in the United States to use the new TomotherapyHD, a comprehensive, image guided radiation therapy system that enables Cancer Care Partners to more efficiently treat complex tumors with improved precision.

18 Mar 2011

GHDX presents Oncotype DX breast cancer test study results at St. Gallen conference

Genomic Health, Inc. today announced results from nine studies utilizing the Oncotype DX test in early-stage breast cancer patients at the 12th Annual St. Gallen International Breast Cancer Conference in St. Gallen, Switzerland.

18 Mar 2011

Scientists receive £5million EU grant to identify gene targets for kidney cancer treatment

An international consortium led by scientists from the Cancer Research UK London Research Institute, The Royal Marsden Hospital and the Technical University of Denmark has been granted nearly £5million by the European Union to identify gene targets for personalised treatment for kidney cancer patients.

18 Mar 2011

INEN, MD Anderson sign sister institution agreement

The University of Texas MD Anderson Cancer Center today signed a sister institution agreement with the National Cancer Institute of Peru. Also known as the Instituto Nacional de Enfermedades Neoplásicas, INEN is Peru's sole national referral center for cancer.

18 Mar 2011

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, has signed an outsource research service agreement with Shenogen Pharma Group to develop therapeutic monoclonal antibodies targeting the ER-alpha 36 receptor for cancer treatment.

16 Mar 2011

Researcher argues against use of Cop1-inhibitory drugs for cancer treatment

Jean-Christophe Marine strongly argues against the use of Cop1-inhibitory drugs. The protein Cop1 has -for a long time - been seen as an attractive drug target for cancer. But Jean-Christophe Marine found out that Cop1 acts as a tumor suppressor, and thus inhibits tumor formation. His new data will have direct implications for the development of cancer drug targets.

16 Mar 2011

TESE offers fertility to male cancer survivors

An intricate procedure that finds and carefully removes individual sperm from testicular tissue has made fathers of men who were once considered sterile due to prior cancer treatment, say researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center who pioneered the technique.

16 Mar 2011

First ever light-activated, non-surgical treatment for HPV and pre-cancerous lesions of the cervix

A new non-surgical, tissue-preserving therapeutic procedure is being developed to more effectively remove HPV infection and treat precursors of cervical cancer.

16 Mar 2011

Prophylactic PEG placement prior to HNC therapy associated with high rate of non use

Impairment of oral intake occurs in the majority of patients with head and neck cancer (HNC) receiving chemoradiotherapy. Placement of prophylactic percutaneous endoscopic gastrostomy (PEG) tube in asymptomatic newly diagnosed HNC before chemoradiation is a common practice in some centers. In some studies, PEG has been associated with a decrease in treatment related weight loss in patients with HNC, but no studies have examined the utilization rate.

16 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

AYA cancer patients require targeted care, say experts

Adolescents and young adults are neither children nor adults and those affected by cancer require targeted care that crosses the boundaries between pediatric and adult oncology, according to several pioneers in this still-developing field of adolescent and young adult oncology.

15 Mar 2011

TESE surgical technique can help men with childhood cancer experience parenthood

A new study has shown that a surgical technique called microdissection testicular sperm extraction can effectively locate and extract viable sperm in more than one-third of adult male childhood cancer survivors who were previously considered sterile due to prior chemotherapy treatment.

15 Mar 2011

Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.

14 Mar 2011

Cancer Treatment News and Research

Researchers create new computational model to understand animal cell behavior

John Muir Health provides new cancer treatment using Varian's RapidArc radiation therapy

MnSOD oral drug can protect against lung cancer radiation therapy

SCCA, ProCure to open new proton therapy center for cancer treatment

Five year course of tamoxifen can offer long-term benefit for women with breast cancer

Sarsia Seed provides follow-up funding for APIM Therapeutics

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Cancer Care Partners first in U.S. to use new, advanced cancer treatment

GHDX presents Oncotype DX breast cancer test study results at St. Gallen conference

Scientists receive £5million EU grant to identify gene targets for kidney cancer treatment

INEN, MD Anderson sign sister institution agreement

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

Researcher argues against use of Cop1-inhibitory drugs for cancer treatment

TESE offers fertility to male cancer survivors

First ever light-activated, non-surgical treatment for HPV and pre-cancerous lesions of the cervix

Prophylactic PEG placement prior to HNC therapy associated with high rate of non use

Apeiron in antitumor substances deal with Cleveland Clinic

AYA cancer patients require targeted care, say experts

TESE surgical technique can help men with childhood cancer experience parenthood

Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

Cancer Research - Second Edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News